Asprosin has been found to play an important and complex role in metabolic and metabolic diseases, with significantly increased serum Asprosin levels in patients with obesity [4], type 2 diabetes mellitus (T2DM) [5], diabetic nephropathy (DN) [6], polycystic ovary syndrome (PCOS) [7], and nonalcoholic fatty liver disease (NAFLD) [8]. Here, FBN1 is linked to Obesity.